Tag: strains

NexZen Extracts Expands Indoor-Grown THCA Flower Lineup with 11 New Strains

Recent lab results proved the Company’s hypothesis that disguising cancer cells to look like common infectious diseases can trick immune cells into attacking the malignant cells

Clinically-Inspired Daily Formula Highlights Cognitive Clarity, Focus, and Mental Energy for Adults Over 50

Experts Reveal 2025 Dog Gut Health Findings, Ingredient Transparency Push, and the Rise of Targeted Canine Probiotics

NexZen Extracts, a premium name in hemp-derived cannabinoid products, has been officially recognized as the Choice of THCA flower brand of 2025

New RxAir400 Pro UV-C bulb replacement cartridge provides 18,000 vs 9,000 hr. use.

Check out Exhale’s new premium Delta 8 flower strains: Hawaiian Haze for euphoria & Northern Lights for relaxation. Best option for balanced highs & therapeutic benefits.

Allschwil, Switzerland, July 29, 2025

WALTHAM, Mass., July 28, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the U.S. Food and Drug Administration (FDA) has approved EMPAVELI^® (pegcetacoplan) as the first treatment for C3 glomerulopathy (C3G) or primary immune complex membranoproliferative glomerulonephritis (IC-MPGN) in patients 12 years of age and older, to reduce proteinuria. C3G and primary IC-MPGN are rare kidney diseases, affecting 5,000 people in the United States.¹

Wuppertal, Germany, July 24, 2025 - Aicuris Anti-infective Cures AG today announced the completion of patient enrollment in its pivotal Phase 3 trial, PRIOH-1, evaluating pritelivir for the treatment of refractory and/or treatment resistant herpes simplex virus (HSV) infections in immunocompromised patients. The company’s lead candidate is a small molecule specifically inhibiting the viral helicase-primase complex, which represents a novel mechanism of action distinct from current HSV therapies.